Christopher Harden, MD : Research

The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as…

Investigator

Christopher Harden

Status

Accepting Candidates

Ages

40 Years - N/A

Sexes

All

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal…

Investigator

Christopher Harden

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Investigator

Christopher Harden

Status

Accepting Candidates

Ages

21 Years - N/A

Sexes

All